MX2024005336A - Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta. - Google Patents
Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.Info
- Publication number
- MX2024005336A MX2024005336A MX2024005336A MX2024005336A MX2024005336A MX 2024005336 A MX2024005336 A MX 2024005336A MX 2024005336 A MX2024005336 A MX 2024005336A MX 2024005336 A MX2024005336 A MX 2024005336A MX 2024005336 A MX2024005336 A MX 2024005336A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- beta chain
- mediated immunity
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274446P | 2021-11-01 | 2021-11-01 | |
| US202163274449P | 2021-11-01 | 2021-11-01 | |
| US202163274430P | 2021-11-01 | 2021-11-01 | |
| PCT/US2022/079051 WO2023077155A1 (en) | 2021-11-01 | 2022-11-01 | Compositions and methods for the modulation of beta chain-mediated immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005336A true MX2024005336A (es) | 2024-07-22 |
Family
ID=84364285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005336A MX2024005336A (es) | 2021-11-01 | 2022-11-01 | Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250092134A1 (enExample) |
| EP (2) | EP4426734A1 (enExample) |
| JP (1) | JP2024543019A (enExample) |
| KR (1) | KR20240099397A (enExample) |
| CN (1) | CN119390841A (enExample) |
| AU (1) | AU2022377084A1 (enExample) |
| CA (1) | CA3237038A1 (enExample) |
| IL (1) | IL312464A (enExample) |
| MX (1) | MX2024005336A (enExample) |
| WO (1) | WO2023077155A1 (enExample) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN119954959A (zh) * | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
-
2022
- 2022-11-01 EP EP22813861.6A patent/EP4426734A1/en active Pending
- 2022-11-01 CN CN202411513821.5A patent/CN119390841A/zh active Pending
- 2022-11-01 WO PCT/US2022/079051 patent/WO2023077155A1/en not_active Ceased
- 2022-11-01 CA CA3237038A patent/CA3237038A1/en active Pending
- 2022-11-01 MX MX2024005336A patent/MX2024005336A/es unknown
- 2022-11-01 IL IL312464A patent/IL312464A/en unknown
- 2022-11-01 JP JP2024525726A patent/JP2024543019A/ja active Pending
- 2022-11-01 AU AU2022377084A patent/AU2022377084A1/en active Pending
- 2022-11-01 EP EP24222564.7A patent/EP4524160A3/en active Pending
- 2022-11-01 US US18/706,417 patent/US20250092134A1/en active Pending
- 2022-11-01 KR KR1020247018329A patent/KR20240099397A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119390841A (zh) | 2025-02-07 |
| AU2022377084A1 (en) | 2024-06-20 |
| EP4426734A1 (en) | 2024-09-11 |
| IL312464A (en) | 2024-06-01 |
| JP2024543019A (ja) | 2024-11-19 |
| EP4524160A2 (en) | 2025-03-19 |
| EP4524160A3 (en) | 2025-09-24 |
| WO2023077155A1 (en) | 2023-05-04 |
| CA3237038A1 (en) | 2023-05-04 |
| US20250092134A1 (en) | 2025-03-20 |
| KR20240099397A (ko) | 2024-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21087921A (es) | Materiales y métodos para modular la inmunidad mediada por células t | |
| CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
| CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
| CL2023001338A1 (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| UY39127A (es) | Materiales y métodos para modular la inmunidad mediada por cadena delta | |
| CL2019002566A1 (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| UY39415A (es) | Métodos y composiciones para modular la inmunidad mediada por cadenas beta | |
| MX2020008184A (es) | Receptores de antigeno quimericos dirigidos a cd70. | |
| MX2024009272A (es) | Constructos de anticuerpos de acidos nucleicos optimizados. | |
| MX2017011329A (es) | Productos terapeuticos de anticuerpos que se enlazan a cd47. | |
| BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| CO2017010583A2 (es) | Compuestos de pirazol y método para elaborar y usar los compuestos | |
| MX2019003376A (es) | Tratamiento de aav de la enfermedad de huntington. | |
| BR112022027101A2 (pt) | Anticorpos multiespecíficos que se ligam a bcma | |
| UY37494A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| CL2021000650A1 (es) | Moduladores de la expresión de pnpla3 | |
| ECSP22078815A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| CO7061040A2 (es) | Anticuerpos contra la metaloproteinasa de la matriz 9 | |
| AR047759A1 (es) | Derivados de fenil - piperazina como moduladores de receptores muscarnicos | |
| CL2025002873A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| MX2021014594A (es) | Procedimiento de una etapa para producir un oleogel proteico. | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| CO2021007006A2 (es) | Moduladores de la expresión de irf5 |